Figure 1: Methylation profiling identifies three molecular subgroups of DIPG. Our results highlight the many pathways to tumorigenesis in DIPG. This complexity needs to be considered when designing ...

(Philadelphia, PA) – Researchers at the University of Pennsylvania School of Medicine have located the "skeleton key," a gene that, when damaged, causes the body's skeletal muscles and soft connective ...

A study found that an inhibitor of an enzyme called ACVR1 slows tumor growth and increases survival in an animal model of diffuse intrinsic pontine glioma (DIPG) -- the most deadly brain tumor in ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Baylor College of Medicine has synthesized activin receptor type-1 (ACVR1; ALK2; ACTR-I) and/or serine/threonine-protein kinase receptor R3 (ACVRL1; ALK1) inhibitors reported to be useful for the ...

A new type of drug that targets a genetic weakness in an untreatable childhood brain cancer could become the first ever treatment designed to target the disease. The prototype treatment could also ...

GSK plc announced the European Commission granted marketing authorisation for Omjjara (momelotinib), a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. Omjjara is the first ...

Fibrodysplasia ossificans progressiva is an incredibly rare disease, striking just one out of every two million people. It’s also an incredibly astonishing disease. A single mutation to a single gene ...

Researchers working with mice believe there's hope for patients with a rare genetic disorder that turns their muscle into bone, in essence immobilizing them in an extra skeleton. The disease, ...

For patients with a rare genetic disorder that turns their muscles into bone, there is new hope. The disease is called fibrodysplasia ossificans progressiva (FOP), or "stone man syndrome." It ...